AllSquare Wealth Management LLC Sells 2,000 Shares of Pfizer Inc. (NYSE:PFE)

AllSquare Wealth Management LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 30.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,638 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. AllSquare Wealth Management LLC’s holdings in Pfizer were worth $123,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Swedbank AB raised its stake in shares of Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after purchasing an additional 37,636 shares in the last quarter. United Bank raised its stake in shares of Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 1,277 shares in the last quarter. Prospera Financial Services Inc lifted its holdings in shares of Pfizer by 1.1% during the 3rd quarter. Prospera Financial Services Inc now owns 109,731 shares of the biopharmaceutical company’s stock worth $3,177,000 after acquiring an additional 1,169 shares during the period. Avior Wealth Management LLC boosted its position in shares of Pfizer by 1.6% during the 3rd quarter. Avior Wealth Management LLC now owns 52,177 shares of the biopharmaceutical company’s stock valued at $1,510,000 after acquiring an additional 798 shares in the last quarter. Finally, Segall Bryant & Hamill LLC bought a new stake in Pfizer in the third quarter valued at about $2,123,000. 68.36% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of a number of analyst reports. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday. Finally, UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Price Performance

Shares of PFE stock opened at $26.17 on Friday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm’s 50 day moving average is $26.18 and its 200-day moving average is $27.07. The firm has a market capitalization of $148.29 billion, a price-to-earnings ratio of 18.56, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.